RADICAVA ORS Drug Patent Profile

Which patents cover Radicava Ors, and when can generic versions of Radicava Ors launch?

Radicava Ors is a drug marketed by Kk Bcj-94 and is included in one NDA. There are eleven patents protecting this drug and one Paragraph IV challenge.

This drug has forty-three patent family members in twenty countries.

The generic ingredient in RADICAVA ORS is edaravone. Five suppliers are listed for this compound. Additional details are available on the edaravone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Radicava Ors

A generic version of RADICAVA ORS was approved as edaravone by DR REDDYS on May 6^th, 2024.

Summary for RADICAVA ORS

International Patents:	43
US Patents:	11
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	5
Drug Prices:	Drug price information for RADICAVA ORS
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RADICAVA ORS
DailyMed Link:	RADICAVA ORS at DailyMed

See drug prices for RADICAVA ORS

Recent Clinical Trials for RADICAVA ORS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Oliver Blanchard	PHASE2
Université de Montréal	PHASE2
Auzone Biological Technology Pty Ltd	Phase 1

See all RADICAVA ORS clinical trials

Paragraph IV (Patent) Challenges for RADICAVA ORS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RADICAVA ORS	Oral Suspension	edaravone	105 mg/5 mL	215446	1	2023-04-20

US Patents and Regulatory Information for RADICAVA ORS

RADICAVA ORS is protected by eleven US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kk Bcj-94	RADICAVA ORS	edaravone	SUSPENSION;ORAL	215446-001	May 12, 2022		RX	Yes	Yes	12,310,946
Kk Bcj-94	RADICAVA ORS	edaravone	SUSPENSION;ORAL	215446-001	May 12, 2022		RX	Yes	Yes	10,987,341		Y
Kk Bcj-94	RADICAVA ORS	edaravone	SUSPENSION;ORAL	215446-001	May 12, 2022		RX	Yes	Yes	12,194,025
Kk Bcj-94	RADICAVA ORS	edaravone	SUSPENSION;ORAL	215446-001	May 12, 2022		RX	Yes	Yes
Kk Bcj-94	RADICAVA ORS	edaravone	SUSPENSION;ORAL	215446-001	May 12, 2022		RX	Yes	Yes	12,285,409		Y

International Patents for RADICAVA ORS

When does loss-of-exclusivity occur for RADICAVA ORS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

China

Denmark

European Patent Office

Finland

Hungary

Israel

Japan

Mexico

Philippines

Poland

Portugal

Singapore

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RADICAVA ORS around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	2021005144	SUSPENSION DE EDARAVONA PARA ADMINISTRACION ORAL. (EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION.)
Japan	WO2022102737
Japan	7828317
Mexico	2023009973
Israel	319280

Market Dynamics and Financial Trajectory for RADICAVA ORS

Last updated: March 10, 2026

RADICAVA ORS (edaravone) is an orphan drug approved in the U.S. for the treatment of amyotrophic lateral sclerosis (ALS). Since its launch, its market position has been shaped by regulatory, competitive, and reimbursement factors affecting its sales performance.

Regulatory and Approval Status

• FDA Approval: May 2017 for ALS treatment.
• European Market: Authorized in Europe under the name Radicava for ALS.
• Orphan Drug Designation: Continues to benefit from orphan status, which provides market exclusivity and tax incentives.

Market Entry and Adoption

• The drug was introduced as an intravenous infusion, with subsequent development to an oral formulation (RADICAVA ORS) approved in December 2022.

• Oral Formulation Impact: Expected to increase adherence, improve quality of life, and expand patient uptake.

• Pricing Strategy:

  • Par with IV formulation at approximately $146,000 annually per patient in the U.S. (excluding insurance rebates).
  • Price reflects high-cost, small-market profile typical of ALS medications.

Market Size and Penetration

• ALS Prevalence: Estimated at 16,000 in the U.S., with approximately 6,000 new cases annually.
• Market Penetration:
  • Initial penetration focused on specialized neurology centers.
  • As of 2023, estimates suggest 20-30% market penetration, corresponding to roughly 1,200-1,800 annual patients.
• Sales Figures:
  • 2020: $120 million.
  • 2021: $160 million.
  • 2022 (post-oral launch): projected at $180-$200 million.

Competitive Landscape

• Main Competitors:

  • Riluzole (Rilutek): First-line ALS treatment with global sales over $150 million annually.
  • Edaravone (IV): Same mechanism, branded as Radicava, with similar sales to RADICAVA ORS pre-launch.
  • Emerging candidates: No approved alternative therapies targeting ALS symptom management or disease progression reversal.

• Market Dynamics:

  • Oral formulation poses a competitive advantage over IV delivery.
  • Limited pipeline of alternative ALS therapies diminishes immediate competitive threat.
  • Insurance coverage and reimbursement policies influence access and revenue.

Financial Trajectory and Outlook

Revenue Growth

Year	Estimated Revenue	Growth Rate	Comment
2020	$120 million	—	Launch phase; primarily IV formulation
2021	$160 million	33%	Increased awareness and coverage
2022	$180-200 million	13-25%	Introduction of RADICAVA ORS, expanded patient base

Drivers of Revenue

• Increased adoption of the oral formulation.
• Expansion into international markets.
• Broader insurance reimbursement coverage.

Challenges and Risks

• Pricing pressures from payers.
• Clinical trial results affecting perceived efficacy.
• Competitive entry if new therapies emerge.
• Manufacturing capacity constraints given small patient population.

Long-Term Outlook

• Revenue growth may plateau absent pipeline expansion or label extensions.
• Ongoing competitive threat is limited, but pipeline ALS drugs could alter the landscape.
• Potential partnership or licensing deals may influence sales trajectory.

Market Trends and Policy Impact

• Pricing and Access:

  • Payer negotiations in the U.S. focus on cost-effectiveness.
  • Orphan drug status sustains higher price points.

• Regulatory Environment:

  • Continued support for rare disease development.
  • Possible incentives for expanding indications.

• Global Expansion:

  • Entry into European and Asian markets could increase sales.
  • Approval timelines and healthcare infrastructure influence speed.

Key Takeaways

• RADICAVA ORS's launch as an oral formulation has expanded its market potential.
• The small ALS market limits total sales but sustains high per-patient pricing.
• Market growth depends on increased uptake, reimbursement policies, and international expansion.
• Competition remains low, but pipeline developments could introduce future risks.
• Revenue projections indicate steady growth through 2023-2025, with potential stabilization afterward.

FAQs

1. What is the primary driver for RADICAVA ORS market growth?
The main driver is increased patient adherence due to the oral formulation, coupled with expanding insurance coverage and international market entry.

2. How does RADICAVA ORS compare price-wise to other ALS therapies?
Pricing remains consistent with the IV formulation at approximately $146,000 annually per patient, which is within the high-cost range typical for orphan drugs.

3. What are the main competitive threats?
Existing alternatives like Riluzole and IV edaravone hold market share. Future pipeline drugs could introduce additional competition.

4. How does reimbursement impact RADICAVA ORS sales?
Insurance and Medicare coverage significantly influence patient access, thereby affecting sales. Favorable reimbursement policies support growth.

5. What is the potential for international sales expansion?
Regulatory approvals in Europe, Asia, and other regions could boost revenue. The timeline depends on regional regulatory processes and healthcare infrastructure.

---

References:

[1] FDA. (2017). Radicava approval letter.
[2] European Medicines Agency. (2022). Radicava approval details.
[3] IQVIA. (2022). U.S. ALS market report.
[4] EvaluatePharma. (2022). Orphan drug sales data.
[5] Company financial filings and earnings reports.